Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Inclusion criteria

• ✓. Adult ( ≥18 years of age), female or male participant with measurable (per RECIST v1.1), unresectable locally advanced or metastatic TNBC
• ✓. Documentation of histologically or cytologically confirmed ER-negative, PR-negative, and HER2-negative tumor per the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (ASCO/CAP) criteria.
• ✓. Measurable disease as defined by RECIST v1.1.
• ✓. Considered to be eligible to receive sacituzumab govitecan-hziy treatment, in the Investigator's judgment.
• ✓. Participants must have received 2 or more prior lines of systemic therapy, at least one of them in the metastatic setting.
• ✓. Radiation therapy for metastatic disease is permitted as long as the participant has at least 1 measurable lesion that has not been irradiated. Participants should be sufficiently recovered from the effects of radiation as determined by the Investigator but must have completed radiotherapy at least 2 weeks prior to enrollment.
• ✓. ECOG performance status of 0 or 1.
• ✓. Adequate organ function as demonstrated by the following laboratory values:

Exclusion criteria